Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 7/2003

01.07.2003 | Review Article

Topical Acne Drugs

Review of Clinical Properties, Systemic Exposure, and Safety

verfasst von: Arash Akhavan, Dr Susan Bershad

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 7/2003

Einloggen, um Zugang zu erhalten

Abstract

This review examines the commonly available topical acne agents and factors that determine their percutaneous absorption. Reported and theoretical adverse effects from systemic exposure are detailed.
The topical retinoid class, which includes tretinoin, adapalene and tazarotene, and the topical antibacterials, clindamycin and erythromycin, are regulated by prescription in most countries. Used appropriately, the above-mentioned drugs deliver, at most, miniscule amounts of active ingredient into the circulation. Clear-cut links to systemic toxicity in humans are practically nonexistent, except in the case of topical clindamycin, which has been associated with diarrhea rarely, and there have been 2 cases of pseudomembranous colitis reported. Birth defects have occurred in two patients treated with tretinoin and one patient treated with adapalene, but causation was not proven. Another prescription drug, 20% azelaic acid, is associated with relatively high systemic exposure, which is presumed innocuous because it is a normal dietary constituent whose endogenous levels are not altered by topical use.
Benzoyl peroxide, salicylic acid, sulfur, and sodium sulfacetamide are available in concentrations of 2% or more in over-the-counter acne treatments and some prescription products. All of these agents are known to exhibit some degree of percutaneous absorption. They remain largely unregulated because, other than skin irritation, only local allergic contact dermatitis from benzoyl peroxide in about 2.5% of patients and rare local and systemic hypersensitivity reactions from sodium sulfacetamide have been reported. Salicylism has occurred using methyl salicylate ointments and high concentrations of salicylic acid on widespread areas of hyperkeratotic skin, but there are no known cases resulting from salicylic acid acne products.
Caution is advised in special circumstances, such as during childhood, pregnancy, lactation and concomitant therapy with other drugs, because relevant studies are lacking. Animal data support avoidance of many topical agents, particularly known teratogens such as retinoids and salicylic acid, in pregnant women. Salicylate avoidance is advised during lactation, because aspirin use carries the risk of bleeding disorders in nursing infants.
Fußnoten
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literatur
1.
Roberts J. Skin conditions of youths 12–17 years, United States. vital and health statistics: Series 11. Data from the National Health Survey, Data from the health examination survey; no. 157. DHEW publication no. (HRA) 76–1639, 1976
2.
Krowchuk DP, Stancin T, Keskinen R, et al. The psychosocial effects of acne on adolescents. Pediatr Dermatol 1991 Dec; 8 (4): 332–8PubMedCrossRef
3.
Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls: an early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130: 308–14PubMedCrossRef
4.
Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997 Jan; 136 (1): 66–70PubMedCrossRef
5.
Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998 Apr; 134 (4): 454–8PubMedCrossRef
6.
Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne: a twin study. Br J Dermatol 1988 Mar; 118 (3): 393–6PubMedCrossRef
7.
Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production: studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993 Feb; 76 (2): 524–8PubMedCrossRef
8.
Marynick SP, Chakmakjian ZH, McCaffree DL, et al. Androgen excess in cystic acne. N Engl J Med 1983 Apr 28; 308 (17): 981–6PubMedCrossRef
9.
Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983 Jul; 81 (1): 70–4PubMedCrossRef
10.
Rasmussen JE. Diet and acne. Int J Dermatol 1977 Jul-Aug; 16 (6): 488–92
11.
Fulton Jr JE, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA 1969 Dec 15; 210 (11): 2071–4PubMedCrossRef
12.
13.
14.
Kersey P, Sussman M, Dahl M. Delayed skin test reactivity to Propionibacterium acnes correlates with severity of inflammation in acne vulgaris. Br J Dermatol 1980 Dec; 103 (6): 651–5PubMedCrossRef
15.
Mills Jr OH, Kligman AM. Assay of comedolytic activity in acne patients. Acta Derm Venereol 1983; 63 (1): 68–71PubMed
16.
Goldstein JA, Comite H, Mescon H, et al. Isotretinoin in the treatment of acne: histologic changes, sebum production, and clinical observations. Arch Dermatol 1982; 118 (8): 555–8PubMedCrossRef
17.
Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai J Med 2001; 68 (4–5): 279–86PubMed
18.
19.
Kawada A, Aragane Y, Kameyama H, et al. Acne phototherapy with a high-intensity, enhanced, narrow-band, blue light source: an open study and in vitro investigation. J Dermatol Sci 2002; 30 (2): 129–35PubMedCrossRef
20.
Paithankar DY, Ross EV, Saleh BA, et al. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002; 31 (2): 106–14PubMedCrossRef
21.
Schaefer H. Penetration and percutaneous absorption of topical retinoids: a review. Skin Pharmacol 1993; 6 Suppl. 1: 17–23CrossRef
22.
Physicians’ desk reference. 56th ed. Montvale (NJ): Medical Economics Company Inc, 2002
23.
Jensen BK, McGann LA, Kachevsky V, et al. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991; 24 (3): 425–8PubMedCrossRef
24.
Rougier A, Dupuis D, Lotte C, et al. The measurement of the stratum corneum reservoir: a predictive method for in vivo percutaneous absorption studies: influence of application time. J Invest Dermatol 1985; 84 (1): 66–8PubMedCrossRef
25.
Bershad S, Poulin YP, Berson DS, et al. Topical retinoids in the treatment of acne vulgaris. Cutis 1999 Aug; 64 (2 Suppl.): 8–20PubMed
26.
Bershad S, Kranjac Singer G, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002; 138 (4): 481–9PubMedCrossRef
27.
Rougier A, Lotte C, Maibach HI. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: predictive assessment by the stripping method. J Pharm Sci 1987; 76 (6): 451–4PubMedCrossRef
28.
Lotte C, Wester RC, Rougier A, et al. Racial differences in the in vivo percutaneous absorption of some organic compounds: a comparison between black, Caucasian and Asian subjects. Arch Dermatol Res 1993; 284 (8): 456–9PubMedCrossRef
29.
Dupuis D, Rougier A, Roguet R, et al. The measurement of the stratum corneum reservoir: a simple method to predict the influence of vehicles on in vivo percutaneous absorption. Br J Dermatol 1986; 115 (2): 233–8PubMedCrossRef
30.
Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S67–73CrossRef
31.
Kligman AM, Fulton Jr JE, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99 (4): 469–76PubMedCrossRef
32.
Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35 (6): 1332–8PubMed
33.
Petkovich M, Brand NJ, Krust A, et al. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330 (6147): 444–50PubMedCrossRef
34.
Mangelsdorf DJ, Ong ES, Dyck JA, et al. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345 (6272): 224–9PubMedCrossRef
35.
Bershad S. Developments in topical retinoid therapy for acne. Semin Cutan Med Surg 2001; 20 (3): 154–61PubMedCrossRef
36.
Weiss JS, Ellis CN, Headington JT, et al. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA 1988; 259 (4): 527–32PubMedCrossRef
37.
Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol 2001 Dec; 137 (12): 1597–604PubMed
38.
Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37 (2 Pt 3): S18–24CrossRef
39.
Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37 (1): 85–92PubMedCrossRef
40.
Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22 (3): 235–46PubMed
41.
Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19 (9): 2456–71PubMed
42.
Marcelo CL, Madison KC. Regulation of the expression of epidermal keratinocyte proliferation and differentiation by vitamin A analogs. Arch Dermatol Res 1984; 276 (6): 381–9PubMedCrossRef
43.
Stadler R, Muller R, Detmar M, et al. Retinoids and keratinocyte differentiation in vitro. Dermatologica 1987; 175 Suppl. 1: 45–55PubMedCrossRef
44.
Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992; 14 (6): 773–80PubMed
45.
Roos TC, Jugert FK, Merk HF, et al. Retinoid metabolism in the skin. Pharmacol Rev 1998; 50 (2): 315–33PubMed
46.
Mills Jr OH, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58 (6): 555–7PubMed
47.
Amblard P, Bazex A, Beylot C, et al. The association tretinoin-erythromycin base: a new topical treatment for acne: results of a multicentric trial on 347 cases (authors transl). Sem Hop 1980; 56 (17–18): 911–5PubMed
48.
Gould DJ, Ead R, Cunliffe WJ. Oral tetracycline and retinoic acid gel in acne. Practitioner 1978; 221 (1322): 268–71PubMed
49.
Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin 1977; 5 (3): 266–8PubMedCrossRef
50.
Swinyer LJ, Swinyer TA, Britt MR. Topical agents alone in acne: a blind assessment study. JAMA 1980; 243 (16): 1640–3PubMedCrossRef
51.
Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976; 216 (1291): 106–9PubMed
52.
Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67 (6 Suppl.): 4–9PubMed
53.
Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998; 139 Suppl. 52: 41–7CrossRef
54.
Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998; 139 Suppl. 52: 26–33CrossRef
55.
Lucky AW, Cullen SI, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38 (4): S24–30CrossRef
56.
Lucky AW, Cullen SI, Jarratt MT, et al. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38 (4): S17–23CrossRef
57.
Cortes JE, Kantarjian H, O’Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73 (12): 2946–52PubMedCrossRef
58.
Fritsch PO, Honigsmann H, Jaschke E, et al. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol 1978; 70 (4): 178–82PubMedCrossRef
59.
Stuttgen G, Ippen H, Mahrle G. Oral vitamin A acid in treatment of dermatoses with pathologic keratinization. Int J Dermatol 1977; 16 (6): 500–2PubMedCrossRef
60.
Lucek RW, Colburn WA. Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 1985; 10 (1): 38–62PubMedCrossRef
61.
Latriano L, Tzimas G, Wong F, et al. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol 1997; 36 (3 Pt 2): S37–46CrossRef
62.
Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 1998; 11 Suppl. 1: S13–9CrossRef
63.
Buchan P, Eckhoff C, Caron D, et al. Repeated topical administration of all-trans-retinoic acid and plasma levels of retinoic acids in humans. J Am Acad Dermatol 1994; 30 (3): 428–34PubMedCrossRef
64.
Clucas A, Verschoore M, Sorba V, et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997; 36 (6 Pt 2): S116–8CrossRef
65.
Shibata K, Shimamoto Y, Ishibashi S, et al. Life-threatening hepatic toxicity caused by all-trans-retinoic acid in a patient with acute promyelocytic leukaemia. Clin Lab Haematol 1994; 16 (2): 191–5PubMedCrossRef
66.
Windhorst DB, Nigra T. General clinical toxicology of oral retinoids. J Am Acad Dermatol 1982; 6 (4 Pt 2 Suppl.): 675–82PubMedCrossRef
67.
Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother 1998; 32 (4): 505–6PubMedCrossRef
68.
Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream [letter]. Lancet 1992; 339 (8794): 687PubMedCrossRef
69.
Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313 (14): 837–41PubMedCrossRef
70.
71.
Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341 (8854): 1181–2PubMedCrossRef
72.
Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300 (7): 329–33PubMedCrossRef
73.
Tang GW, Russell RM. 13-cis-retinoic acid is an endogenous compound in human serum. J Lipid Res 1990; 31 (2): 175–82PubMed
74.
75.
Chalker DK, Lesher Jr JL, Smith Jr JG, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987; 17 (2 Pt 1): 251–4PubMedCrossRef
76.
Langner A, Stapor W, Donald AE, et al. Double-blind, placebo-controlled study of the efficacy and safety of isotretinoin cream (0.05% w/w and 0.10% w/w) with sunscreens in the treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2000; 11: 7–14CrossRef
77.
Cunliffe WJ, Glass D, Goode K, et al. A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Derm Venereol 2001; 81 (1): 14–7PubMedCrossRef
78.
Chen C, Jensen BK, Mistry G, et al. Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. J Clin Pharmacol 1997; 37 (4): 279–84PubMed
79.
Brazzell RK, Colburn WA. Pharmacokinetics of the retinoids isotretinoin and etretinate: a comparative review. J Am Acad Dermatol 1982; 6 (4 Pt 2 Suppl.): 643–51PubMedCrossRef
80.
Reniers DE, Howard JM. Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann Pharmacother 2001; 35 (10): 1214–6PubMedCrossRef
81.
Rappaport EB, Knapp M. Isotretinoin embryopathy: a continuing problem. J Clin Pharmacol 1989; 29 (5): 463–5PubMed
82.
83.
Braun JT, Franciosi RA, Mastri AR, et al. Isotretinoin dysmorphic syndrome. Lancet 1984; I (8375): 506–7CrossRef
84.
Hersh JH, Danhauer DE, Hand ME, et al. Retinoic acid embryopathy: timing of exposure and effects on fetal development. JAMA 1985; 254 (7): 909–10PubMedCrossRef
85.
Roche Laboratories Inc. SMART guide to best practices: system to manage accutane related teratogenicity. Nutley (NJ): Roche Laboratories Inc, 2001
86.
Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313 (16): 981–5PubMedCrossRef
87.
Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988; 42 (5): 399–400PubMed
88.
Tangrea JA, Kilcoyne RF, Taylor PR, et al. Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin. Arch Dermatol 1992; 128 (7): 921–5PubMedCrossRef
89.
Archer CB, Elias PM, Lowe NJ, et al. Extensive spinal hyperostosis in a patient receiving isotretinoin: progression after 4 years of etretinate therapy. Clin Exp Dermatol 1989; 14 (4): 319–21PubMedCrossRef
90.
McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991; 127 (3): 341–6PubMedCrossRef
91.
Marini JC, Hill S, Zasloff MA. Dense metaphyseal bands and growth arrest associated with isotretinoin therapy. Am J Dis Child 1988; 142 (3): 316–8PubMed
92.
Martin P, Manley PN, Depew WT, et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987; 93 (3): 606–9PubMed
93.
Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45 (4): 515–9PubMedCrossRef
94.
Marsden JR. Effect of isotretinoin on carbamazepine pharmacokinetics. Br J Dermatol 1988; 119 (3): 403–4PubMedCrossRef
95.
Gottfried NS. Pseudo-tumor cerebri and acne [letter]. Mil Med 1991; 156 (8): A5
96.
Cunliffe WJ, Caputo R, Dreno B, et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris: a European multicentre trial. J Dermatol Treatment 1997; 8: 173–8CrossRef
97.
Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34 (3): 482–5PubMedCrossRef
98.
Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S17–24CrossRef
99.
Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997; 36 (6 Pt 2): S119–25CrossRef
100.
Rolland A, Wagner N, Chatelus A, et al. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993; 10 (12): 1738–44PubMedCrossRef
101.
Jamoulle JC, Grandjean L, Lamaud E, et al. Follicular penetration and distribution of topically applied CD 271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol 1990; 94 (5): 731–2PubMedCrossRef
102.
Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy [letter]. Lancet 1997; 350 (9074): 339PubMedCrossRef
103.
Chandraratna RA. Tazarotene: first of a new generation of receptor-selective retinoids. Br J Dermatol 1996; 135 Suppl. 49: 18–25CrossRef
104.
Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001; 67 (6 Suppl.): 10–6PubMed
105.
Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999; 63 (6): 349–54PubMed
106.
Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997; 37 (2 Pt 3): S12–7CrossRef
107.
Duvic M. Pharmacologic profile of tazarotene. Cutis 1998; 61 (2 Suppl.): 22–6PubMed
108.
Marks R. Early clinical development of tazarotene. Br J Dermatol 1996; 135 Suppl. 49: 26–31CrossRef
109.
Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37 (4): 273–87PubMedCrossRef
110.
Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol 1998; 39 (4 Pt 2): S134–8CrossRef
111.
Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43 (2 Pt 3): S31–5CrossRef
112.
Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Int J Dermatol 1977; 16 (5): 413–7PubMedCrossRef
113.
Cunliffe WJ, Stainton C, Forster RA. Topical benzoyl peroxide increases the sebum excretion rate in patients with acne. Br J Dermatol 1983; 109 (5): 577–9PubMedCrossRef
114.
Nacht S, Gans EH, McGinley KJ, et al. Comparative activity of benzoyl peroxide and hexachlorophene: in vivo studies against propionibacterium acnes in humans. Arch Dermatol 1983; 119 (7): 577–9PubMedCrossRef
115.
Tucker SB, Tausend R, Cochran R, et al. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110 (4): 487–92PubMedCrossRef
116.
Swinyer LJ, Baker MD, Swinyer TA, et al. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 119 (5): 615–22PubMedCrossRef
117.
Burke B, Eady EA, Cunliffe WJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108 (2): 199–204PubMedCrossRef
118.
Chalker DK, Shalita A, Smith Jr JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9 (6): 933–6PubMedCrossRef
119.
Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37 (4): 590–5PubMedCrossRef
120.
Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134 (1): 107–13PubMedCrossRef
121.
Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8 (1): 41–5PubMedCrossRef
122.
Morelli R, Lanzarini M, Vincenzi C, et al. Contact dermatitis due to benzoyl peroxide. Contact Dermatitis 1989; 20 (3): 238–9PubMedCrossRef
123.
Zbinden G. Scientific opinion on the carcinogenic risk due to topical administration of benzoylperoxide for the treatment of acne vulgaris. Pharmacol Toxicol 1988; 63 (5): 307–9PubMedCrossRef
124.
Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 394–7
125.
Cambazard F. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris. J Eur Acad Dermatol Venereol 1998; 11 Suppl. 1: S20–7CrossRef
126.
Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris: a cooperative clinical study. Arch Dermatol 1981; 117 (8): 482–5PubMedCrossRef
127.
Parker F. A comparison of clindamycin 1% solution versus clindamycin 1% gel in the treatment of acne vulgaris. Int J Dermatol 1987; 26 (2): 121–2PubMedCrossRef
128.
Goltz RW, Coryell GM, Schnieders JR, et al. A comparison of Cleocin T 1 percent solution and Cleocin T 1 percent lotion in the treatment of acne vulgaris. Cutis 1985; 36 (3): 265–8PubMed
129.
Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 2001; 67 (2 Suppl.): 13–20PubMed
130.
Barza M, Goldstein JA, Kane A, et al. Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol 1982; 7 (2): 208–14PubMedCrossRef
131.
Stoughton RB, Cornell RC, Gange RW, et al. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980; 26 (4): 424–5, 429
132.
Thomsen RJ, Stranieri A, Knutson D, et al. Topical clindamycin treatment of acne: clinical, surface lipid composition, and quantitative surface microbiology response. Arch Dermatol 1980; 116 (9): 1031–4PubMedCrossRef
133.
Gordon RC, Regamey C, Kirby WM. Serum protein binding of erythromycin, lincomycin, and clindamycin. J Pharm Sci 1973; 62 (7): 1074–7PubMedCrossRef
134.
Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. 3rd ed. Philadelphia (PA): American College of Physicians, 1994
135.
Fass RJ, Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 1972; 263 (5): 368–82PubMedCrossRef
136.
DeHaan RM, Metzler CM, Schellenberg D, et al. Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol 1973; 13 (5): 190–209PubMed
137.
Fleming GF, Crowe GR. Granulocytopenia due to clindamycin [letter]. Med J Aust 1976; 1 (3): 70PubMed
138.
Swenson RM, Michaelson TC, Daly MJ, et al. Clindamycin in infections of the female genital tract. Obstet Gynecol 1974; 44 (5): 699–702PubMed
139.
Vikenes K, Lund-Tonnesen S, Schreiner A. Clostridium difficile-associated diarrhea after short term vaginal administration of clindamycin. Am J Gastroenterol 1999; 94 (7): 1969–70PubMedCrossRef
140.
Elmore M, Rissing JP, Rink L, et al. Clindamycin-associated hepatotoxicity. Am J Med 1974; 57 (4): 627–30PubMedCrossRef
141.
Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001; 7 (8): 421–7PubMedCrossRef
142.
Feingold DS, Chen WC, Chou DL, et al. Induction of colitis in hamsters by topical application of antibiotics. Arch Dermatol 1979; 115 (5): 580–1PubMedCrossRef
143.
Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986; 122 (5): 583–4PubMedCrossRef
144.
Milstone EB, McDonald AJ, Scholhamer Jr CF. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981; 117 (3): 154–5PubMedCrossRef
145.
[No authors listed]. The transfer of drugs and other chemicals into human breast milk. Pediatrics 1983; 72 (3): 375–83
146.
Al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. Can J Anaesth 1995; 42 (7): 614–7PubMedCrossRef
147.
Igarashi K, Ishitsuka H, Kaji A. Comparative studies on the mechanism of action of lincomycin, streptomycin, and erythromycin. Biochem Biophys Res Commun 1969; 37 (3): 499–504PubMedCrossRef
148.
Pochi PE, Bagatell FK, Ellis CN, et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41 (2): 132–6PubMed
149.
Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117 (9): 551–3PubMedCrossRef
150.
Puschmann M, Meyer-Rohn J. The efficacy of a topical preparation containing erythromycin in the treatment of acne. Dermatologica 1982; 164 (5): 343–9PubMedCrossRef
151.
Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5 (1): 37–42PubMed
152.
Schmidt JB, Knobler R, Neumann R, et al. [External erythromycin therapy of acne]. Z Hautkr 1983; 58 (24): 1754–60PubMed
153.
Schmidt JB, Thurner J, Poitscheck C, et al. [Local acne therapy with erythromycin]. Z Hautkr 1982; 57 (2): 69–77PubMed
154.
Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979; 24 (5): 385–96PubMedCrossRef
155.
Avila P, Capella D, Laporte JR, et al. Which salt of erythromycin is most hepatotoxic [letter]? Lancet 1988; I (8594): 1104CrossRef
156.
Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984; 92 (6): 678–84PubMed
157.
Jorro G, Morales C, Braso JV, et al. Anaphylaxis to erythromycin. Ann Allergy Asthma Immunol 1996; 77 (6): 456–8PubMedCrossRef
158.
Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002; 156 (7): 647–50PubMed
159.
Gilman AG, Rall TW, Nies AS, et al., eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York (NY): Pergamon Press, 1990
160.
Olsen TG. Therapy of acne. Med Clin North Am 1982; 66 (4): 851–71PubMed
161.
Hjorth N. Traditional topical treatment of acne. Acta Derm Venereol Suppl (Stockh) 1980; Suppl. 89: 53–6
162.
Olin B, editor. Facts and comparisons. St Louis (MO): JB Lippincott Co, 1990
163.
Schwarb FP, Gabard B, Rufli T, et al. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology 1999; 198 (1): 44–51PubMedCrossRef
164.
Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996; 30 (9): 935–40PubMed
165.
Pertoldi F, D’Orlando L, Mercante WP. [Acute salicylate intoxication after trancutaneous absorption]. Minerva Anestesiol 1999; 65 (7–8): 571–3PubMed
166.
Candy JM, Morrison C, Paton RD, et al. Salicylate toxicity masquerading as malignant hyperthermia. Paediatr Anaesth 1998; 8 (5): 421–3PubMedCrossRef
167.
Germann R, Schindera I, Kuch M, et al. [Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris]. Hautarzt 1996; 47 (8): 624–7PubMedCrossRef
168.
Chiaretti A, Schembri Wismayer D, Tortorolo L, et al. Salicylate intoxication using a skin ointment. Acta Paediatr 1997; 86 (3): 330–1PubMedCrossRef
169.
Poe TE, Scott RB, Keith Jr JF. Drug interactions with furosemide [letter]. J Fam Pract 1984; 18 (2): 204PubMed
170.
Pec J, Strmenova M, Palencarova E, et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 1992; 50 (4): 307–9PubMed
171.
Davies MG, Briffa DV, Greaves MW. Systemic toxicity from topically applied salicylic acid. BMJ 1979; 1 (6164): 661PubMedCrossRef
172.
Cross SE, Anderson C, Thompson MJ, et al. Is there tissue penetration after application of topical salicylate formulations [letter]? Lancet 1997; 350 (9078): 636PubMedCrossRef
173.
Raschke R, Arnold-Capell PA, Richeson R, et al. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med 1991; 151 (3): 591–3PubMedCrossRef
174.
Yokoyama A, Takakubo F, Eto K, et al. Teratogenicity of aspirin and its metabolite, salicylic acid, in cultured rat embryos. Res Commun Chem Pathol Pharmacol 1984; 46 (1): 77–91PubMed
175.
176.
Danto JL, Maddin WS, Stewart WD, et al. A controlled trial of benzoyl peroxide and precipitated sulfur cream in acne vulgaris. Appl Ther 1966; 8 (7): 624–5PubMed
177.
Wilkinson RD, Adam JE, Murray JJ, et al. Benzoyl peroxide and sulfur: foundation for acne management. CMAJ 1966; 95 (1): 28–9
178.
Breneman DL, Ariano MC. Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. Int J Dermatol 1993; 32 (5): 365–7PubMedCrossRef
179.
Pandey J, Chellani H, Garg M, et al. Congenital sulfhemoglobin and transient methemoglobinemia secondary to diarrhoea. Indian J Pathol Microbiol 1996; 39 (3): 217–20PubMed
180.
Blum JE, Coe FL. Metabolic acidosis after sulfur ingestion. N Engl J Med 1977; 297 (16): 869–70PubMedCrossRef
181.
Olansky S. Old drug – in a new system – revisited. Cutis 1977; 19 (6): 852–4PubMed
182.
Genvert GI, Cohen EJ, Donnenfeld ED, et al. Erythema multiforme after use of topical sulfacetamide. Am J Ophthalmol 1985; 99 (4): 465–8PubMed
183.
Rubin Z. Ophthalmic sulfonamide-induced Stevens-Johnson syndrome. Arch Dermatol 1977; 113 (2): 235–6PubMedCrossRef
184.
Gottschalk HR, Stone OJ. Stevens-Johnson syndrome from ophthalmic sulfonamide. Arch Dermatol 1976; 112 (4): 513–4PubMedCrossRef
185.
Spes CH, Angermann CE, Stempfle HU, et al. Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration. Clin Investig 1992; 70 (9): 752–4PubMedCrossRef
186.
Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl 1979; 624: 106–10PubMed
187.
Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41 (5): 780–98PubMedCrossRef
188.
Mackrides PS, Shaughnessy AF. Azelaic acid therapy for acne. Am Fam Physician 1996; 54 (8): 2457–9PubMed
189.
Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989; 143: 31–4
190.
Hjorth N, Graupe K. Azelaic acid for the treatment of acne: a clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh) 1989; 143: 45–8
191.
Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989; 143: 58–61
192.
Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris: comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989; 143: 35–9
193.
Passi S, Nazzaro-Porro M, Picardo M, et al. Metabolism of straight saturated medium chain length (C9 to C12) dicarboxylic acids. J Lipid Res 1983; 24 (9): 1140–7PubMed
194.
Willshaw HE, Rubinstein K. Azelaic acid in the treatment of ocular and adnexal malignant melanoma. Br J Ophthalmol 1983; 67 (1): 54–7PubMedCrossRef
Metadaten
Titel
Topical Acne Drugs
Review of Clinical Properties, Systemic Exposure, and Safety
verfasst von
Arash Akhavan
Dr Susan Bershad
Publikationsdatum
01.07.2003
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 7/2003
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304070-00004

Weitere Artikel der Ausgabe 7/2003

American Journal of Clinical Dermatology 7/2003 Zur Ausgabe

Leading Article

Prevalence of Joint Disease in Patients with Psoriasis

Therapy in Practice

Dermabrasion in Dermatology

Pharmacovigilance

Cutaneous Drug Reaction Case Reports

Review Article

Isotretinoin Use and Subsequent Depression and Suicide

Therapy in Practice

Cutaneous Lupus Erythematosus

Original Research Article

The Efficacy of Calcipotriol + Acitretin Combination Therapy for Psoriasis

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise